X-linked Lymphoproliferative Syndrome 1 clinical trials
36 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones look like a fit.
- Tolerance Through Mixed Chimerism (Sip-Tego)
- CAR-T Cell Therapy for Desensitization in Kidney Transplantation
- Belatacept in Heart Transplantation
- Advancing Transplantation Outcomes in Children
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
- A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
- Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
- Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
- Study of PAT in Patients With Solid Tumor Cancers
- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- A Study of SIPLIZUMAB in AILD and LT Patients
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
- A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Belatacept in De Novo Heart Transplantation
- CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
- Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
- Genetic Studies of Chronic Active Epstein-Barr Disease
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
- (TNX-1500) in Kidney Transplant Recipients
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
- Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
- Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
- Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
- Effects of Antiviral Therapies on Epstein-Barr Virus Replication
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “X-linked Lymphoproliferative Syndrome 1” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.